Sight Sciences (SGHT) director awarded 28,261 RSUs worth about $130,000
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Encrantz Staffan reported acquisition or exercise transactions in this Form 4 filing.
Sight Sciences director Staffan Encrantz received an equity award in the form of restricted stock units (RSUs). He was granted 28,261 RSUs under the company’s Non-Employee Director Compensation Program, with the number of units based on approximately $130,000 of common stock at the closing price on June 4, 2026.
The RSUs vest on the earlier of June 4, 2027 or the company’s 2027 annual stockholder meeting, contingent on his continued board service. Following this grant, his direct holdings include 1,391,922 shares of common stock plus the 28,261 RSUs, totaling 1,420,183 shares. Additional indirect positions are reported through the 1997 Staffan and Margareta Encrantz Revocable Trust and Allegro Investment Fund, L.P., with beneficial ownership of those shares disclaimed as described in the footnotes.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Encrantz Staffan
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 28,261 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 1,420,183 shares (Direct, null);
Common Stock — 632,456 shares (Indirect, See footnote)
Footnotes (1)
- Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to approximately $130,000 of shares of Common Stock as determined by the closing price on the grant date, June 4, 2026. The RSUs vest on the earlier of June 4, 2027 and the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date. Includes (i)1,391,922 shares of Common Stock and (ii) 28,261 RSUs which are subject to vesting as reported herein. These shares of Common Stock are held of record by the 1997 Staffan Encrantz and Margareta Encrantz Revocable Trust (the "Trust"). The Reporting Person is a trustee of the Trust and may be deemed to beneficially own the shares held by the Trust for purposes of Rule 13d-3 under the Securities Exchange Act of 1934 (the "Exchange Act"). The Reporting Person disclaims beneficial ownership of the shares held by the Trust (and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 under the Exchange Act or for any other purpose), except to the extent of his pecuniary interest therein, if any. These shares of Common Stock are held of record by Allegro Investment Fund, L.P. ("Allegro Investment Fund"). The Reporting Person is the Chairman and CEO and sole director of Allegro Investment Inc., which is the investment manager of Allegro Investment Fund, and may be deemed to beneficially own the shares held by Allegro Investment Fund for purposes of Rule 13d-3 under the Exchange Act. However, the Reporting Person does not have any pecuniary interest in the shares held by Allegro Investment Fund and disclaims beneficial ownership with respect to all such shares. Accordingly, these shares are being reported in this report voluntarily by the Reporting Person for informational purposes only and shall not be deemed an admission that the Reporting Person is the beneficial owner of any such shares for purposes of Section 16 under the Exchange Act or for any other purpose.
Key Figures
RSU grant size: 28,261 RSUs
Grant value: $130,000
Direct holdings after grant: 1,420,183 shares
+3 more
6 metrics
RSU grant size
28,261 RSUs
Grant to director on June 4, 2026
Grant value
$130,000
Approximate value based on closing price June 4, 2026
Direct holdings after grant
1,420,183 shares
1,391,922 shares plus 28,261 RSUs following transaction
Trust-held shares
5,086,920 shares
Common Stock held by 1997 Staffan and Margareta Encrantz Revocable Trust
Allegro Investment Fund shares
632,456 shares
Common Stock held by Allegro Investment Fund, L.P.
RSU vesting date
June 4, 2027
Or earlier 2027 annual meeting, subject to continued service
Key Terms
restricted stock units ("RSUs"), Non-Employee Director Compensation Program, beneficially own, pecuniary interest, +2 more
6 terms
restricted stock units ("RSUs") financial
"Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Non-Employee Director Compensation Program financial
"made to the Reporting Person under the Issuer's Non-Employee Director Compensation Program"
beneficially own financial
"may be deemed to beneficially own the shares held by the Trust"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
pecuniary interest financial
"except to the extent of his pecuniary interest therein, if any"
Rule 13d-3 regulatory
"may be deemed to beneficially own the shares held by Allegro Investment Fund for purposes of Rule 13d-3"
Rule 13d-3 defines who is treated as the beneficial owner of a company’s shares for U.S. securities disclosure rules — essentially anyone who has the power to vote or direct how shares are voted, or the power to buy or sell them, even if they don’t hold the certificates. For investors this matters because crossing certain ownership thresholds triggers public filing and disclosure obligations and signals potential control or influence, much like having the keys to a car implies you can drive it even if it’s registered to someone else.
Section 16 regulatory
"shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
FAQ
What did Sight Sciences (SGHT) director Staffan Encrantz receive in this Form 4?
Director Staffan Encrantz received a grant of 28,261 restricted stock units (RSUs) in Sight Sciences. The grant was made under the Non-Employee Director Compensation Program and represents approximately $130,000 of common stock based on the closing price on June 4, 2026.
How is the value of the RSU grant for Sight Sciences (SGHT) director determined?
The RSU grant value is approximately $130,000 of Sight Sciences common stock. The company calculated the number of RSUs, 28,261, using the closing share price on the June 4, 2026 grant date, aligning director compensation with the company’s stock performance.
When do the RSUs granted to the Sight Sciences (SGHT) director vest?
The 28,261 RSUs vest on the earlier of June 4, 2027 or Sight Sciences’ 2027 annual meeting of stockholders. Vesting is conditioned on Staffan Encrantz continuing to serve as a director on the company’s board through the applicable vesting date.
What are Staffan Encrantz’s direct holdings in Sight Sciences (SGHT) after this grant?
After the RSU grant, Encrantz’s direct position includes 1,391,922 shares of common stock and 28,261 RSUs. Combined, this totals 1,420,183 shares, reflecting his personal equity stake excluding separately reported indirect holdings through other entities.